DIEGO
RINCÓN RODRÍGUEZ
Profesor asociado
Hospital Universitario La Paz
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario La Paz (11)
2024
2022
-
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study
Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 342-349
2020
-
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis
Hepatology, Vol. 72, Núm. 6, pp. 1924-1934
-
Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients
Liver International, Vol. 40, Núm. 9, pp. 2215-2227
2019
2017
-
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237
-
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311
-
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort
Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148
-
Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection
Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1
-
Similar effectiveness of direct-acting antiviral against hepatitis C virus in patients with and without HIV infection
AIDS, Vol. 31, Núm. 9, pp. 1253-1260
2016
-
Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma
Hepatology, Vol. 63, Núm. 2, pp. 488-498